Lyra Therapeutics, Inc.LYRANASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -64.15% | +43.15% | -65.60% | -69.40% | -87.18% |
| Gross Profit Growth | +0.00% | +242.62% | -53.79% | -102.84% | -138.46% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +14.93% | +6.33% | +2.73% | -97.94% | -97.30% |
| Weighted Average Shares Diluted Growth | +14.93% | +5.82% | +2.73% | -97.94% | -97.30% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -34.68% | -53.47% | -60.21% | -44.42% | -44.50% |
| Book Value per Share Growth | -78.70% | -87.81% | -95.14% | +154.15% | +0.00% |
| Debt Growth | +461.59% | +27.90% | -11.90% | -11.62% | -11.17% |
| R&D Expense Growth | -52.28% | -47.77% | -73.06% | -61.47% | -31.43% |
| SG&A Expenses Growth | -21.43% | -17.08% | -43.92% | -31.87% | -45.66% |